Drug Profile
TAK 426
Alternative Names: PIZV; Purified inactivated Zika virus vaccine - Takeda; TAK-426; Zika virus vaccine - TakedaLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Zika virus infection
Most Recent Events
- 13 Mar 2024 Takeda terminates a phase II trial in Zika virus infection (Prevention) in USA prior to enrolment due to business reason and change in Zika virus epidemiology (IM, Injection) (NCT05469802)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in USA (IM, Injection)
- 30 Jun 2023 Discontinued - Phase-I for Zika virus infection (Prevention) in Puerto Rico (IM) (Takeda pipeline; February 2024)